RhumbLine Advisers’s ALX Oncology ALXO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$204K Buy
147,003
+39,101
+36% +$75.5K ﹤0.01% 3260
2026
Q2
$223K Buy
+107,902
New +$193K ﹤0.01% 3226
2025
Q2
– Sell
-46,302
Closed -$28.8K – 4145
2025
Q1
$28.8K Buy
46,302
+3,786
+9% +$4.54K ﹤0.01% 3679
2024
Q4
$71K Buy
42,516
+405
+1% +$623 ﹤0.01% 3578
2024
Q3
$76.6K Sell
42,111
-13,109
-24% -$48.7K ﹤0.01% 3586
2024
Q2
$333K Buy
55,220
+5,360
+11% +$65.9K ﹤0.01% 2938
2024
Q1
$556K Buy
49,860
+1,706
+4% +$24K ﹤0.01% 2608
2023
Q4
$717K Sell
48,154
-2,803
-6% -$26.6K ﹤0.01% 2458
2023
Q3
$245K Buy
50,957
+607
+1% +$3.29K ﹤0.01% 3044
2023
Q2
$378K Buy
50,350
+11,443
+29% +$74.9K ﹤0.01% 2869
2023
Q1
$176K Buy
38,907
+930
+2% +$7.04K ﹤0.01% 2760
2022
Q4
$428K Buy
37,977
+5,467
+17% +$61.4K ﹤0.01% 2540
2022
Q3
$311K Buy
32,510
+3,523
+12% +$41.1K ﹤0.01% 2712
2022
Q2
$235K Buy
28,987
+10,614
+58% +$116K ﹤0.01% 2865
2022
Q1
$311K Buy
18,373
+1,054
+6% +$18K ﹤0.01% 2632
2021
Q4
$372K Sell
17,319
-302
-2% -$13K ﹤0.01% 2628
2021
Q3
$1.3M Buy
17,621
+1,415
+9% +$94.3K ﹤0.01% 2111
2021
Q2
$886K Sell
16,206
-2,069
-11% -$124K ﹤0.01% 2298
2021
Q1
$1.35M Buy
18,275
+7,311
+67% +$575K ﹤0.01% 2071
2020
Q4
$945K Buy
10,964
+2,727
+33% +$164K ﹤0.01% 2157
2020
Q3
$311K Buy
+8,237
New +$324K ﹤0.01% 2505

Other funds holding ALXO

RhumbLine Advisers's ALXO Position: Q3 2026 in Review

RhumbLine Advisers increased its ALX Oncology (ALXO) stake by 36% in Q3 2026, buying an estimated $75.5K and bringing the position to 147,003 shares worth $204K. The position accounts for ﹤0.01% of the portfolio, ranked #3260.

RhumbLine Advisers first reported a position in ALXO in Q3 2020 and has held it in 21 quarters since. The position peaked at $1.35M in Q1 2021. 112 funds tracked by Wall St. Rank hold ALXO as of Q3 2026.

  • RhumbLine Advisers held 147,003 shares of ALX Oncology worth $204K as of Q3 2026.
  • RhumbLine Advisers bought 39,101 ALX Oncology shares in Q3 2026, an estimated $75.5K.
  • ALX Oncology made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #3260 holding.
  • RhumbLine Advisers first reported a position in ALX Oncology in Q3 2020 and has held it in 21 quarters since.
  • RhumbLine Advisers's ALX Oncology position peaked at $1.35M in Q1 2021.
  • 112 funds tracked by Wall St. Rank held ALX Oncology as of Q3 2026.

Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.